At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, Zoran Gatalica, MD, DSc, from Caris Life Sciences, Phoenix, AZ, discusses a study evaluating the differences in expression of multiple biomarkers of targeted biological therapies, immune checkpoint inhibitors and chemotherapeutic agents between primary and metastatic tumors in patients with non-small cell lung cancer (NSCLC).